
Oncology NEWS International
- Oncology NEWS International Vol 17 No 3
- Volume 17
- Issue 3
RFA provides sustained pain relief in osteoid osteoma
CT-guided radiofrequency ablation (RFA) offers long-term pain reduction in patients with osteoid osteoma, making RFA a viable alternative to open surgery, according to researchers from Seoul, South Korea.
SAN FRANCISCO-CT-guided radiofrequency ablation (RFA) offers long-term pain reduction in patients with osteoid osteoma, making RFA a viable alternative to open surgery, according to researchers from Seoul, South Korea.
“Surgery is considered if pain persists, but open surgical excision is known to have high morbidity, and recurrence is not uncommon,” Ki Sun Sung, MD, PhD, said at the 2007 American Academy of Orthopedic Surgeons meeting (abstract 464). Dr. Sung and his co-authors are from Sungkyunkwan University School of Medicine and Samsung Medical Center.
This retrospective study focused on 28 patients, between 1995 and 2005, with osteoid osteoma, all of whom did not respond to conservative treatment with anti-inflammatory drugs. Patients underwent RFA and had at least 2 years of follow-up data available. Of the 28 patients, 26 had primary tumors and two had recurring disease. The nidus size ranged from 2 to 14 mm in diameter. During CT-guided RFA, the lesion was heated to 80 to 90 C for an average of 6.5 minutes.
RFA was deemed technically successful in 27 cases. There was one skin burn complication. All patients were discharged 1.8 days after the procedure. At 2 years post-RFA, 90% of patients said they had a complete loss of symptoms. An additional RFA procedure was required in three subjects for a recurrence rate of about 10%. These patients said they had pain relief after the second treatment. All patients remained symptom free 6 years after RFA.
Articles in this issue
over 17 years ago
Recentin headed to phase III in first-line colon caover 17 years ago
Topo 2 alpha test FDA approvedover 17 years ago
Renal ca surgery often determined by doctors’ practice styleover 17 years ago
Partial nephrectomy underutilized for small renal tumorsover 17 years ago
Most older men with early-stage cancer can avoid treatmentover 17 years ago
SERM reduces ADT side effectsover 17 years ago
New serum biomarker appears to detect colon cancerover 17 years ago
Hypofractionated IMRT does not increase sexual side effectsover 17 years ago
Surface mapping aligns patients for external beam PBIover 17 years ago
Is benefit of trastuzumab limited to first 18 months?Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































